New Immunoassay Developed for Zika Virus Detection
By LabMedica International staff writers Posted on 31 Jan 2017 |
The new assay can improve patient care by enabling differential diagnostics according to the World Health Organization (WHO) test algorithm. It is capable of detecting Zika virus during the acute phase of infection, approximately a few days after the onset of symptoms.
The CE-marked Novagnost Zika virus IgM µ-capture assay, developed by Siemens Healthineers of Siemens Healthcare, is now commercially available in many countries (currently not available in the US). The assay is user-friendly, utilizing the same dilution and reagents as other Novagnost assays. It is validated for use on plasma and serum, and can be performed on the BEP III and BEP 2000 Advance Systems (currently not available in the US).
Together with the recently announced real-time molecular VERSANT Zika RNA 1.0 Assay (kPCR), Siemens Healthineers thus now offers Zika assays both for immunoassay and molecular detection. The VERSANT Zika assay is currently intended for research use only (RUO) in regions outside of the US. In July 2016, it received Emergency Use Authorization (EUA) from the US Food and Drug Administration (FDA), allowing for unapproved medical products or unapproved uses of approved medical products to be used in an emergency to diagnose, treat, or prevent serious or life-threatening diseases or conditions caused by chemical, biological, radiological, and nuclear (CBRN) threats when there are no adequate, approved, and available alternatives.
"As the Zika virus continues to rise as a global public health concern, there is an increased focus on detecting the Zika virus during the acute phase of infection," said Franz Walt, president, Laboratory Diagnostics, Siemens Healthineers, "With the introduction of the Novagnost Zika Virus IgM µ-capture Assay, Siemens Healthineers completes laboratories' virus testing menu by delivering assays for both immunoassay and molecular detection."
The CE-marked Novagnost Zika virus IgM µ-capture assay, developed by Siemens Healthineers of Siemens Healthcare, is now commercially available in many countries (currently not available in the US). The assay is user-friendly, utilizing the same dilution and reagents as other Novagnost assays. It is validated for use on plasma and serum, and can be performed on the BEP III and BEP 2000 Advance Systems (currently not available in the US).
Together with the recently announced real-time molecular VERSANT Zika RNA 1.0 Assay (kPCR), Siemens Healthineers thus now offers Zika assays both for immunoassay and molecular detection. The VERSANT Zika assay is currently intended for research use only (RUO) in regions outside of the US. In July 2016, it received Emergency Use Authorization (EUA) from the US Food and Drug Administration (FDA), allowing for unapproved medical products or unapproved uses of approved medical products to be used in an emergency to diagnose, treat, or prevent serious or life-threatening diseases or conditions caused by chemical, biological, radiological, and nuclear (CBRN) threats when there are no adequate, approved, and available alternatives.
"As the Zika virus continues to rise as a global public health concern, there is an increased focus on detecting the Zika virus during the acute phase of infection," said Franz Walt, president, Laboratory Diagnostics, Siemens Healthineers, "With the introduction of the Novagnost Zika Virus IgM µ-capture Assay, Siemens Healthineers completes laboratories' virus testing menu by delivering assays for both immunoassay and molecular detection."
Latest Microbiology News
- Integrated Solution Ushers New Era of Automated Tuberculosis Testing
- Automated Sepsis Test System Enables Rapid Diagnosis for Patients with Severe Bloodstream Infections
- Enhanced Rapid Syndromic Molecular Diagnostic Solution Detects Broad Range of Infectious Diseases
- Clinical Decision Support Software a Game-Changer in Antimicrobial Resistance Battle
- New CE-Marked Hepatitis Assays to Help Diagnose Infections Earlier
- 1 Hour, Direct-From-Blood Multiplex PCR Test Identifies 95% of Sepsis-Causing Pathogens
- Mouth Bacteria Test Could Predict Colon Cancer Progression
- Unique Metabolic Signature Could Enable Sepsis Diagnosis within One Hour of Blood Collection
- Groundbreaking Diagnostic Platform Provides AST Results With Unprecedented Speed
- Simple Blood Test Combined With Personalized Risk Model Improves Sepsis Diagnosis
- Blood Analysis Predicts Sepsis and Organ Failure in Children
- TB Blood Test Could Detect Millions of Silent Spreaders
- New Blood Test Cuts Diagnosis Time for Nontuberculous Mycobacteria Infections from Months to Hours
- New Tuberculosis Test to Expand Testing Access in Low- and Middle-Income Countries
- Rapid Test Diagnoses Tropical Disease within Hours for Faster Antibiotics Treatment
- Rapid Molecular Testing Enables Faster, More Targeted Antibiotic Treatment for Pneumonia